With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

The Food and Drug Administration (FDA) has approved Enflonsia ™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who ...

New members of the Advisory Committee on Immunization Practices have not yet been identified, but they are expected to meet later this month. Separately, the FDA has approved Merck's monoclonal ...

Merck & Co – known as MSD outside the US and Canada – has announced that its respiratory syncytial virus (RSV) preventive ...

The approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.

Adelaide nurse and mother-of-two Deanne Tingey thought her little girl, Winter, was just suffering from a common cold.

As winter settles over Australia, it's not just the drop in temperature we notice - there's also a sharp rise in respiratory illnesses. Most of us are ...